Business · 25/06/2015

FDA Announces Proposed Collection of Information for Postmarketing Adverse Event Reporting

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, requiring pharmaceutical companies to report postmarketing adverse events for nonprescription human drug products marketed without FDA approval.